6 results on '"Corsico, Angelo Guido"'
Search Results
2. Exploring the Role of Immune System and Inflammatory Cytokines in SARS-CoV-2 Induced Lung Disease: A Narrative Review.
- Author
-
Tirelli, Claudio, De Amici, Mara, Albrici, Cristina, Mira, Sabrina, Nalesso, Giulia, Re, Beatrice, Corsico, Angelo Guido, Mondoni, Michele, and Centanni, Stefano
- Subjects
LUNGS ,SARS-CoV-2 ,COVID-19 ,IMMUNE system ,LUNG diseases ,NEUROENDOCRINE cells ,ADULT respiratory distress syndrome - Abstract
Simple Summary: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the pandemic coronavirus disease-2019 (COVID-19), which can lead to severe pneumonia and acute respiratory distress syndrome (ARDS). The immune system plays a key role in the defense against COVID-19. Nonetheless, if dysregulated and hyperactivated, the immune response can trigger the deleterious "cytokine storm". Multiple studies are aimed at finding potential immunomodulators to rebalance the immune response against the virus, thus limiting its dangerous effects. Moreover, the development of vaccines against SARS-CoV-2 has represented a global challenge. The aim of this narrative review is to describe the state-of-the-art knowledge on the immune system response in COVID-19 and to underline the main therapeutic strategies and the key role of vaccines. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative pathogen of coronavirus disease 19 (COVID-19). COVID-19 can manifest with a heterogenous spectrum of disease severity, from mild upper airways infection to severe interstitial pneumonia and devastating acute respiratory distress syndrome (ARDS). SARS-CoV-2 infection may induce an over activation of the immune system and the release of high concentrations of pro-inflammatory cytokines, leading to a "cytokine storm", a recognized pathogenetic mechanism in the genesis of SARS-CoV-2-induced lung disease. This overproduction of inflammatory cytokines has been recognized as a poor prognostic factor, since it can lead to disease progression, organ failure, ARDS and death. Moreover, the immune system shows dysregulated activity, particularly through activated macrophages and T-helper cells and in the co-occurrent exhaustion of lymphocytes. We carried out a non-systematic literature review aimed at providing an overview of the current knowledge on the pathologic mechanisms played by the immune system and the inflammation in the genesis of SARS-CoV-2-induced lung disease. An overview on potential treatments for this harmful condition and for contrasting the "cytokine storm" has also been presented. Finally, a look at the experimented experimental vaccines against SARS-CoV-2 has been included. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Electrophysiological evidence of subclinical trigeminal dysfunction in patients with COVID-19 and smell impairment: A pilot study.
- Author
-
Cosentino, Giuseppe, Maiorano, Eugenia, Todisco, Massimiliano, Prunetti, Paolo, Antoniazzi, Elisa, Tammam, Giulia, Quartesan, Ilaria, Lettieri, Sara, De Icco, Roberto, Corsico, Angelo Guido, Benazzo, Marco, Pisani, Antonio, Tassorelli, Cristina, and Alfonsi, Enrico
- Subjects
COVID-19 ,ELECTROPHYSIOLOGY ,BLINKING (Physiology) ,TRIGEMINAL nerve ,SMELL - Abstract
Background: Smell and taste disturbances are among the most frequent neurological symptoms in patients with COVID-19. A concomitant impairment of the trigeminal nerve has been suggested in subjects with olfactory dysfunction, although it has not been confirmed with objective measurement techniques. In this study, we explored the trigeminal function and its correlations with clinical features in COVID-19 patients with impaired smell perception using electrophysiological testing. Methods: We enrolled 16 consecutive patients with mild COVID-19 and smell impairment and 14 healthy controls (HCs). Olfactory and gustatory symptoms were assessed with self-reported questionnaires. Electrophysiological evaluation of the masseter inhibitory reflex (MIR) and blink reflex (BR) was carried out to test the trigeminal function and its connections within the brainstem. Results: Masseter inhibitory reflex (MIR) analysis revealed higher latency of ipsilateral and contralateral early silent period in patients when compared with HCs. No significant differences between groups were detected as regards the duration of the early and late silent period. However, several patients showed a prolonged duration of the early silent period. BR evaluation disclosed only an increased amplitude of early components in patients. Conclusions: Patients with COVID-19 and smell impairment show a subclinical trigeminal nerve impairment. Trigeminal alterations mainly involve the oligosynaptic pathway, as a result of either direct viral damage or secondary neuroinflammation of the peripheral trigeminal fibers, whereas the polysynaptic ponto-medullary circuits seem to be spared. The prolonged duration of the early silent period and the increased amplitude of early BR response might reflect a compensatory upregulation of the trigeminal function as a consequence of the olfactory dysfunction. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Our recommendations for acute management of COVID-19
- Author
-
Mojoli, Francesco, Mongodi, Silvia, Orlando, Anita, Arisi, Eric, Pozzi, Marco, Civardi, Luca, Tavazzi, Guido, Baldanti, Fausto, Bruno, Raffaele, Iotti, Giorgio Antonio, Marena, Carlo, Calvi, Monica, Grugnetti, Giuseppina, Maurelli, Marco, Muzzi, Alba, Raffaele, Bruno, Lago, Paolo, Marseglia, Gianluigi, Perlini, Stefano, Palo, Alessandra, Oltrona Visconti, Luigi, Corsico, Angelo Guido, Di Sabatino, Antonio, Iotti, Giorgio, Benazzo, Marco, Carlo, Nicora, Antonio, Triarico, Vincenzo, Petronella, and COVID-19 Pavia Crisis Unit
- Subjects
2019-20 coronavirus outbreak ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,COVID-19 ,ARDS ,Acute respiratory failure ,Lung ultrasound ,Novel coronavirus ,Pneumonia, Viral ,MEDLINE ,Critical Care and Intensive Care Medicine ,Severe Acute Respiratory Syndrome ,Antiviral Agents ,Betacoronavirus ,COVID-19 Testing ,medicine ,Viral therapy ,Humans ,Acute management ,Intensive care medicine ,Lung ,Pandemics ,Ultrasonography ,business.industry ,Clinical Laboratory Techniques ,SARS-CoV-2 ,lcsh:Medical emergencies. Critical care. Intensive care. First aid ,lcsh:RC86-88.9 ,COVID-19 Drug Treatment ,Editorial ,Italy ,Practice Guidelines as Topic ,business ,Coronavirus Infections - Published
- 2020
5. Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?
- Author
-
Bari, Elia, Ferrarotti, Ilaria, Saracino, Laura, Perteghella, Sara, Torre, Maria Luisa, Richeldi, Luca, Corsico, Angelo Guido, and De Langhe, Stijn
- Subjects
PULMONARY fibrosis ,COVID-19 pandemic ,STROMAL cells ,MESENCHYMAL stem cells ,COVID-19 - Abstract
To date, more than 100 million people worldwide have recovered from COVID-19. Unfortunately, although the virus is eradicated in such patients, fibrotic irreversible interstitial lung disease (pulmonary fibrosis, PF) is clinically evident. Given the vast numbers of individuals affected, it is urgent to design a strategy to prevent a second wave of late mortality associated with COVID-19 PF as a long-term consequence of such a devastating pandemic. Available antifibrotic therapies, namely nintedanib and pirfenidone, might have a role in attenuating profibrotic pathways in SARS-CoV-2 infection but are not economically sustainable by national health systems and have critical adverse effects. It is our opinion that the mesenchymal stem cell secretome could offer a new therapeutic approach in treating COVID-19 fibrotic lungs through its anti-inflammatory and antifibrotic factors. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use.
- Author
-
Bari, Elia, Ferrarotti, Ilaria, Saracino, Laura, Perteghella, Sara, Torre, Maria Luisa, and Corsico, Angelo Guido
- Subjects
PANDEMICS ,COVID-19 ,COVID-19 pandemic ,STROMAL cells ,MESENCHYMAL stem cells ,INFECTION - Abstract
From the end of 2019, the world population has been faced the spread of the novel coronavirus SARS-CoV-2 responsible for COVID-19 infection. In approximately 14% of the patients affected by the novel coronavirus, the infection progresses with the development of pneumonia that requires mechanical ventilation. At the moment, there is no specific antiviral treatment recommended for the COVID-19 pandemic and the therapeutic strategies to deal with the infection are only supportive. In our opinion, mesenchymal stem cell secretome could offer a new therapeutic approach in treating COVID-19 pneumonia, due to the broad pharmacological effects it shows, including anti-inflammatory, immunomodulatory, regenerative, pro-angiogenic and anti-fibrotic properties. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.